Cidara shares tank af­ter lead an­ti­fun­gal pro­gram flops in PhII

Shares of Cidara Ther­a­peu­tics $CDTX tanked Tues­day morn­ing af­ter the up­start an­ti­fun­gal biotech said its lead pro­gram foundered in Phase II.

In­ves­ti­ga­tors went look­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER